{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05826535",
            "orgStudyIdInfo": {
                "id": "MPCT-012L"
            },
            "organization": {
                "fullName": "ImmPACT Bio",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of IMPT-314 in R/R Aggressive B-cell NHL",
            "officialTitle": "A Phase 1/2 Multi-center Study Evaluating the Safety and Efficacy of IMPT-314, a CD19/20 Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "study-of-impt-in-r-r-aggressive-b-cell-nhl"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-05-09",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-06-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2029-12-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-03-24",
            "studyFirstSubmitQcDate": "2023-04-12",
            "studyFirstPostDateStruct": {
                "date": "2023-04-24",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-03",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-04",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "ImmPACT Bio",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of IMPT-314, a bispecific chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive B-cell NHL. Three cohorts of participants will be enrolled: 1) CAR T na\u00efve after at least two or more prior lines of treatment, 2) CAR T experienced and 3) refractory disease or relapse within one year of first line therapy.\n\nUp to approximately 90 patients (30 per cohort) will be enrolled in dose finding Phase 1 part of the study, which will determine the recommended phase 2 dose.\n\nPhase 2 will enroll up to approximately 60 additional participants (20 per cohort) to evaluate further the safety and efficacy of IMPT-314.\n\nIMPT-314 treatment consists of a single infusion of CAR-transduced autologous T cells administered intravenously after a conditioning chemotherapy regimen consisting of fludarabine and cyclophosphamide, administered over 3 days.\n\nIndividual participants will remain in the active post-treatment period for approximately 2 years. Participants will continue in long-term follow-up for 15 years from treatment."
        },
        "conditionsModule": {
            "conditions": [
                "Relapsed Non-Hodgkin Lymphoma",
                "Refractory Non-Hodgkin Lymphoma"
            ],
            "keywords": [
                "CAR T-cell",
                "Non-Hodgkin Lymphoma",
                "CD19/20",
                "CD19",
                "CD20",
                "NHL",
                "Diffuse Large B-cell lymphoma",
                "DLBCL",
                "Transformed follicular lymphoma",
                "TFL",
                "Primary mediastinal B-cell lymphoma",
                "PMBCL",
                "High-grade B-cell lymphoma",
                "HGBL",
                "follicular lymphoma Grade 3B",
                "large cell follicular lymphoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "Dose finding Phase I followed by a Phase II part. Two Phase I dose levels and one Phase II dose level. Three cohorts in each phase.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "SINGLE",
                    "maskingDescription": "Analysis of response will be performed by Blinded Independent Central Review (BICR) Discordance between the Investigator assessment and BICR assessment will be evaluated for each efficacy endpoints based on tumor assessments if BICR assessments are performed.",
                    "whoMasked": [
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 150,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Phase I Dose Level I CAR T experienced cohort",
                    "type": "EXPERIMENTAL",
                    "description": "Phase I 3+3 design Dose level 1: 1\u00d710e8 (\u00b1 20%) IMPT-314 cells Single dose/infusion during 28 day window",
                    "interventionNames": [
                        "Drug: IMPT-314"
                    ]
                },
                {
                    "label": "Phase I Dose Level II CAR T experienced cohort",
                    "type": "EXPERIMENTAL",
                    "description": "Phase I 3+3 design Dose level 2: 3\u00d710e8 (\u00b1 20%) IMPT-314 cells Single dose/infusion during 28 day window",
                    "interventionNames": [
                        "Drug: IMPT-314"
                    ]
                },
                {
                    "label": "Phase II CAR T experienced cohort",
                    "type": "EXPERIMENTAL",
                    "description": "Single dose determined during Phase I.",
                    "interventionNames": [
                        "Drug: IMPT-314"
                    ]
                },
                {
                    "label": "Phase I Dose Level I CAR T na\u00efve cohort",
                    "type": "EXPERIMENTAL",
                    "description": "Phase I 3+3 design Dose level 1: 1\u00d710e8 (\u00b1 20%) IMPT-314 cells Single dose/infusion during 28 day window",
                    "interventionNames": [
                        "Drug: IMPT-314"
                    ]
                },
                {
                    "label": "Phase I Dose Level II CAR T na\u00efve cohort",
                    "type": "EXPERIMENTAL",
                    "description": "Phase I 3+3 design Dose level 2: 3\u00d710e8 (\u00b1 20%) IMPT-314 cells Single dose/infusion during 28 day window",
                    "interventionNames": [
                        "Drug: IMPT-314"
                    ]
                },
                {
                    "label": "Phase II CAR T na\u00efve cohort",
                    "type": "EXPERIMENTAL",
                    "description": "Single dose determined during Phase I.",
                    "interventionNames": [
                        "Drug: IMPT-314"
                    ]
                },
                {
                    "label": "Phase I Dose Level I Refractory disease or relapse within one year of first line therapy",
                    "type": "EXPERIMENTAL",
                    "description": "Phase I 3+3 design Dose level 1: 1\u00d710e8 (\u00b1 20%) IMPT-314 cells Single dose/infusion during 28 day window",
                    "interventionNames": [
                        "Drug: IMPT-314"
                    ]
                },
                {
                    "label": "Phase I Dose Level II Refractory disease or relapse within one year of first line therapy",
                    "type": "EXPERIMENTAL",
                    "description": "Phase I 3+3 design Dose level 2: 3\u00d710e8 (\u00b1 20%) IMPT-314 cells Single dose/infusion during 28 day window",
                    "interventionNames": [
                        "Drug: IMPT-314"
                    ]
                },
                {
                    "label": "Phase II Refractory disease or relapse within one year of first line therapy",
                    "type": "EXPERIMENTAL",
                    "description": "Single dose determined during Phase I.",
                    "interventionNames": [
                        "Drug: IMPT-314"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "IMPT-314",
                    "description": "CAR T-cell therapy",
                    "armGroupLabels": [
                        "Phase I Dose Level I CAR T experienced cohort",
                        "Phase I Dose Level I CAR T na\u00efve cohort",
                        "Phase I Dose Level I Refractory disease or relapse within one year of first line therapy",
                        "Phase I Dose Level II CAR T experienced cohort",
                        "Phase I Dose Level II CAR T na\u00efve cohort",
                        "Phase I Dose Level II Refractory disease or relapse within one year of first line therapy",
                        "Phase II CAR T experienced cohort",
                        "Phase II CAR T na\u00efve cohort",
                        "Phase II Refractory disease or relapse within one year of first line therapy"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Phase I: Incidence of DLTs and other treatment-emergent adverse events (TEAEs)",
                    "timeFrame": "Baseline to Month 24"
                },
                {
                    "measure": "Phase I: Investigator-assessed complete response (CR) rate",
                    "timeFrame": "Baseline to Month 24"
                },
                {
                    "measure": "Phase I: Proportion of enrolled participants who receive the target dose",
                    "timeFrame": "Baseline to Month 24"
                },
                {
                    "measure": "Phase II: Complete response based on investigator assessment per the Lugano classification",
                    "timeFrame": "Baseline to Month 24"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Phase I and II: Proportion of enrolled participants with no prior exposure to T cell engagers who receive the target dose of IMPT-314",
                    "timeFrame": "Baseline to Month 24"
                },
                {
                    "measure": "Phase I and II: Proportion of enrolled participants with prior exposure to T cell engagers who receive the target dose of IMPT-314",
                    "timeFrame": "Baseline to Month 24"
                },
                {
                    "measure": "Phase I and II: Overall response rate (ORR)",
                    "timeFrame": "Baseline to Month 24"
                },
                {
                    "measure": "Phase I and II: Duration of response (DOR)",
                    "timeFrame": "Baseline to Month 24"
                },
                {
                    "measure": "Phase I and II: Duration of complete response (DOCR)",
                    "timeFrame": "Baseline to Month 24"
                },
                {
                    "measure": "Phase I and II: Progression free survival (PFS)",
                    "timeFrame": "Baseline to Month 24"
                },
                {
                    "measure": "Phase I and II: Overall survival (OS)",
                    "timeFrame": "Baseline to Month 24"
                },
                {
                    "measure": "Phase I and II: Cmax from time 0 to Day 28 (AUC0-28)",
                    "timeFrame": "Baseline to Day 28"
                },
                {
                    "measure": "Phase I and II: Area under the curve from time 0 to Day 28 (AUC0-28)",
                    "timeFrame": "Baseline to Day 28"
                },
                {
                    "measure": "Phase I and II: Persistence of IMPT-314 (Concentration of IMPT-314 cells in peripheral blood).",
                    "timeFrame": "Baseline to Day 28"
                },
                {
                    "measure": "Phase II: Incidence of TEAEs",
                    "timeFrame": "Baseline to Month 24"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age 18 years or older\n2. Willing and able to provide written informed consent\n3. Histologically confirmed aggressive NHL, including the following types defined by the World Health Organization (WHO) 2017:\n\n   * DLBCL\n   * DLBCL arising from follicular lymphoma (Transformed FL)\n   * Primary mediastinal (thymic) large B-cell lymphoma\n   * High-grade large B-cell lymphoma with or without MYC and BCL2 and/or BCL6 rearrangement\n   * Grade 3b follicular lymphoma/Large cell follicular lymphoma\n4. Received at least 1 prior line of therapy. Prior therapy must have included:\n\n   * Anti-CD20 monoclonal antibody\n   * An anthracycline containing chemotherapy regimen\n   * Participants with TFL must have received at least one of their prior lines of therapy after transformation to DLBCL\n5. Relapsed or refractory disease, defined by the following:\n\n   * Disease progression after last regimen (including salvage therapy after autologous stem cell transplantation \\[ASCT\\]). In participants who have only received front-line therapy, progression should be \u226412 months of initiating first-line therapy.\n   * In patients who received two or more lines of therapy, refractory disease is defined as failure to achieve a CR to last line of therapy (including CAR T and/or salvage therapy).\n   * In patients who received one line of therapy, refractory disease is defined as failure to achieve at least a PR after at least 4 cycles of therapy\n6. At least 1 measurable lesion (the Lugano classification). Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy\n7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n8. Absolute neutrophil count (ANC) \u2265 1000/uL\n\nOther protocol-defined criteria apply.\n\nExclusion Criteria:\n\n1. History of malignancy other than non-melanoma skin cancer or carcinoma in situ (e.g., cervix, bladder, breast) unless disease-free for at least 3 years. Participants who have received therapy for a prior malignancy within the prior 3 years, e.g., in the adjuvant setting, are not excluded\n2. Active central nervous system (CNS) involvement by malignancy on magnetic resonance imaging (MRI) or by lumbar puncture. Participants with prior evidence of brain metastasis successfully treated at least 8 weeks prior to enrollment will not be excluded for participation if CNS disease is deemed stable at the time of study enrolment\n3. History of cardiac lymphoma involvement\n4. Ongoing or impending oncologic emergency (e.g., tumor mass effect, tumor lysis syndrome)\n5. Received the following therapies in the specified time frame prior to enrollment/leukapheresis\n\n   1. Any systemic therapy within 2 weeks\n   2. Any systemic inhibitory/stimulatory immune checkpoint molecule therapy within 3 half-lives prior to enrollment (e.g., ipilimumab, nivolumab, pembrolizumab, atezolizumab, OX40 agonists, 4-\n\n      1BB agonists)\n   3. Fludarabine within 12 weeks\n   4. Alemtuzumab, bendamustine or antithymocyte globuline (ATG) within 6 months\n   5. Any T cell engager/bispecific antibody therapy such as CD20/CD3 or CD19/CD3 bispecific antibodies within 4 weeks\n   6. Any experimental therapy within 4 weeks or 5 half-lives (whichever is shorter)\n6. Received radiation therapy within 3 weeks prior to enrollment\n7. Experiencing non-hematologic toxicities due to prior therapy (stable and recovered to grade \u2264 1 or non- clinically significant toxicities such as alopecia are allowed)\n8. History of allogeneic stem cell or solid organ transplantation\n9. Receipt of autologous stem cell transplantation within 6 weeks prior to enrollment\n10. History of prior genetically modified T cell therapy other than a product targeting CD19 with an FMC63-based CAR (e.g., axicabtagene ciloleucel (axi-cel, YESCARTA\u00ae), tisagenlecleucel (tisa-cel, KYMRIAH\u00ae), or lisocabtagene maraleucel (liso-cel, BREYANZI\u00ae). For all other CAR T cell therapy treatments, discussion with the Sponsor's Medical Monitor is required\n11. Primary immunodeficiency\n12. History of autoimmune disease (e.g., Crohn's disease, rheumatoid arthritis, systemic lupus) resulting in end organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years. Participants who have other autoimmune condition(s) considered to be associated with underlying malignancy may be enrolled in the study after discussion with and approval of the Medical Monitor.\n\nOther protocol-defined criteria apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "ImmPACT Bio",
                    "role": "CONTACT",
                    "phone": "818-857-4828",
                    "email": "clinicaltrials@immpact-bio.com"
                }
            ],
            "locations": [
                {
                    "facility": "University of California-Irvine Medical Center",
                    "status": "RECRUITING",
                    "city": "Irvine",
                    "state": "California",
                    "zip": "92697",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Blake Johnson",
                            "role": "CONTACT",
                            "email": "blakej@hs.uci.edu"
                        },
                        {
                            "name": "Stefan Ciurea",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.66946,
                        "lon": -117.82311
                    }
                },
                {
                    "facility": "Cedars-Sinai Medical Center",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90048",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Akil Merchant",
                            "role": "CONTACT",
                            "phone": "310-423-5706",
                            "email": "Akil.Merchant@cshs.org"
                        },
                        {
                            "name": "Akil Merchant",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "University of California, Los Angeles (UCLA) Medical Center",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90095",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Christopher M. Hannigan",
                            "role": "CONTACT",
                            "phone": "310-825-4493",
                            "email": "CHannigan@mednet.ucla.edu"
                        },
                        {
                            "name": "Sara M. Larson",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "University of California (UC) Davis Comprehensive Cancer Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Sacramento",
                    "state": "California",
                    "zip": "95817",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Joseph Tuscano",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.58157,
                        "lon": -121.4944
                    }
                },
                {
                    "facility": "Scripps Clinic",
                    "status": "NOT_YET_RECRUITING",
                    "city": "San Diego",
                    "state": "California",
                    "zip": "92037",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "James Mason",
                            "role": "CONTACT",
                            "email": "Mason.James@scrippshealth.org"
                        },
                        {
                            "name": "James Mason",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.71533,
                        "lon": -117.15726
                    }
                },
                {
                    "facility": "Augusta University Medical Center",
                    "status": "RECRUITING",
                    "city": "Augusta",
                    "state": "Georgia",
                    "zip": "30912",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Amanda Spires",
                            "role": "CONTACT",
                            "phone": "706-721-8981",
                            "email": "amspires@augusta.edu"
                        },
                        {
                            "name": "Locke Bryan",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.47097,
                        "lon": -81.97484
                    }
                },
                {
                    "facility": "St Luke's Cancer Institute",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Boise",
                    "state": "Idaho",
                    "zip": "83712",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "William Kreisle",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.6135,
                        "lon": -116.20345
                    }
                },
                {
                    "facility": "Indiana Blood and Marrow Transplantation",
                    "status": "RECRUITING",
                    "city": "Indianapolis",
                    "state": "Indiana",
                    "zip": "46237",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Melanie Coleman",
                            "role": "CONTACT",
                            "phone": "317-528-7298",
                            "email": "Melanie.Coleman@franciscanalliance.org"
                        },
                        {
                            "name": "Felix Mensah",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.76838,
                        "lon": -86.15804
                    }
                },
                {
                    "facility": "University of Iowa",
                    "status": "RECRUITING",
                    "city": "Iowa City",
                    "state": "Iowa",
                    "zip": "52242",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Umar Farooq",
                            "role": "CONTACT",
                            "phone": "319-356-1616",
                            "email": "umar-farooq@uiowa.edu"
                        },
                        {
                            "name": "Umar Farooq",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.66113,
                        "lon": -91.53017
                    }
                },
                {
                    "facility": "University of Louisville Brown Cancer Center",
                    "status": "RECRUITING",
                    "city": "Louisville",
                    "state": "Kentucky",
                    "zip": "40202",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Mohamed Hegazi",
                            "role": "CONTACT",
                            "phone": "502-562-3367",
                            "email": "mohamed.hegazi@louisville.edu"
                        },
                        {
                            "name": "Mohamed Hegazi",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.25424,
                        "lon": -85.75941
                    }
                },
                {
                    "facility": "Corewell Health",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Grand Rapids",
                    "state": "Michigan",
                    "zip": "49503",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sami Brake",
                            "role": "CONTACT",
                            "phone": "616-486-5933",
                            "email": "sami.brake@corewellhealth.org"
                        },
                        {
                            "name": "Sami brake",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.96336,
                        "lon": -85.66809
                    }
                },
                {
                    "facility": "University of New Mexico Comprehensive Cancer Center",
                    "status": "RECRUITING",
                    "city": "Albuquerque",
                    "state": "New Mexico",
                    "zip": "87131",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Valerie Parks",
                            "role": "CONTACT",
                            "phone": "404-925-0390",
                            "email": "Vparks@salud.unm.edu"
                        },
                        {
                            "name": "Matthew L. Fero",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.08449,
                        "lon": -106.65114
                    }
                },
                {
                    "facility": "Montefiore Medical Center",
                    "status": "RECRUITING",
                    "city": "Bronx",
                    "state": "New York",
                    "zip": "10461",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Dennis Cooper",
                            "role": "CONTACT",
                            "email": "decooper@montefiore.org"
                        },
                        {
                            "name": "Dennis Cooper",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.84985,
                        "lon": -73.86641
                    }
                },
                {
                    "facility": "University of Cincinnati (UC) Physicians Company, LLC",
                    "status": "RECRUITING",
                    "city": "Cincinnati",
                    "state": "Ohio",
                    "zip": "45267",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Tahir Latif",
                            "role": "CONTACT",
                            "phone": "513-558-2115",
                            "email": "tahir.latif@uc.edu"
                        },
                        {
                            "name": "Tahir Latif",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.12713,
                        "lon": -84.51435
                    }
                },
                {
                    "facility": "Baylor University Medical Center",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75246",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Nebu Koshy",
                            "role": "CONTACT",
                            "email": "Nebu.Koshy@BSWHealth.org"
                        },
                        {
                            "name": "Nebu Koshy",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "Huntsman Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Salt Lake City",
                    "state": "Utah",
                    "zip": "84112",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Lindsay Gilstrap",
                            "role": "CONTACT",
                            "phone": "801-213-5652",
                            "email": "Lindsey.Gilstrap@hci.utah.edu"
                        },
                        {
                            "name": "Boyu Hu",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.76078,
                        "lon": -111.89105
                    }
                },
                {
                    "facility": "Intermountain Healthcare",
                    "status": "RECRUITING",
                    "city": "Salt Lake City",
                    "state": "Utah",
                    "zip": "84143",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Bradley Hunter",
                            "role": "CONTACT",
                            "phone": "801-408-1819",
                            "email": "Brad.Hunter@imail.org"
                        },
                        {
                            "name": "Bradley Hunter",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.76078,
                        "lon": -111.89105
                    }
                },
                {
                    "facility": "University of Vermont Cancer Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Burlington",
                    "state": "Vermont",
                    "zip": "05405",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Christa Varnadoe",
                            "role": "CONTACT",
                            "phone": "863-224-9380"
                        },
                        {
                            "name": "Gargi Joshi",
                            "role": "CONTACT",
                            "phone": "857-707-8614"
                        },
                        {
                            "name": "James Gerson",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.47588,
                        "lon": -73.21207
                    }
                },
                {
                    "facility": "Virginia Commonwealth University-Massey Cancer Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Richmond",
                    "state": "Virginia",
                    "zip": "23298",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Kristin Lantis",
                            "role": "CONTACT",
                            "phone": "804-628-6430",
                            "email": "masseybmt@vcu.edu"
                        },
                        {
                            "name": "William Clark",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.55376,
                        "lon": -77.46026
                    }
                },
                {
                    "facility": "Medical College of Wisconsin",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Milwaukee",
                    "state": "Wisconsin",
                    "zip": "53226",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Mehdi Hamadani",
                            "role": "CONTACT",
                            "email": "mhamadani@mcw.edu"
                        },
                        {
                            "name": "Medhi Hamadani",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.0389,
                        "lon": -87.90647
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008223",
                    "term": "Lymphoma"
                },
                {
                    "id": "D000008228",
                    "term": "Lymphoma, Non-Hodgkin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11220",
                    "name": "Lymphoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18828",
                    "name": "Lymphoma, B-Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M18831",
                    "name": "Lymphoma, Large B-Cell, Diffuse",
                    "relevance": "LOW"
                },
                {
                    "id": "M11221",
                    "name": "Lymphoma, Follicular",
                    "relevance": "LOW"
                },
                {
                    "id": "M3724",
                    "name": "Aggression",
                    "relevance": "LOW"
                },
                {
                    "id": "M11222",
                    "name": "Lymphoma, Non-Hodgkin",
                    "asFound": "Non-Hodgkin Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3543",
                    "name": "Lymphosarcoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T640",
                    "name": "B-cell Lymphoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T1866",
                    "name": "Diffuse Large B-Cell Lymphoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T2361",
                    "name": "Follicular Lymphoma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}